GLI provided comments to FDA on the importance of patient preference information (PPI)
Global Liver Institute provided comments to the U.S. Food and Drug Administration (FDA) on the importance of patient preference information (PPI). As described by the FDA, PPI captures the value patients place on features of medical devices. Well-designed and well-conducted PPI studies elicit which attributes are important to patients, how important they are, and what trade-offs patients are willing to make.
GLI founder and CEO, Donna R. Cryer, JD stated, “When I founded Global Liver Institute, it was clear to me that patient perspectives were lacking in research and policy discussions, particularly related to the differences among patients that are under-represented in the data. We appreciate that the FDA is prioritizing efforts to address such challenges…We look forward to continuing to play a role in the development of revised guidance on PPI to ensure that the patient voice is genuinely reflected in the attributes identified and incorporated into clinical trials.”
About Global Liver Institute
Global Liver Institute (GLI) was built to solve the problems that matter to liver patients, equipping advocates to improve the lives of individuals and families impacted by liver disease. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. GLI believes liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI is the only patient-created, patient-driven nonprofit organization tackling liver health and all liver disease holistically, operating globally. Follow GLI on Facebook, Instagram, LinkedIn, and YouTube.